Chad Worz, PharmD, BCGP, FASCP, discusses the Main Street Pharmacy Access Act, a revolutionary pharmacy-focused bill moving through Congress.
News|Articles|September 22, 2023
Survey: Taking the Pulse of the Pharmacy Profession
Advertisement
Since 2020, Drug Topics has partnered with the healthcare business of LexisNexis Risk Solutions to take the pulse of the pharmacy profession. We invite you to take the 2023 survey, providing a look back at 2023 and a snapshot of what 2024 may hold for the pharmacy profession.
Advertisement
Related to this article
Data show that commercially and Medicaid-insured children with chronic or immunocompromising conditions incur 2- to 3-fold higher costs.
Researchers assess the neurological outcomes of over 200,000 children exposed to COVID-19 before birth.
Results show consistent improvements in wakefulness, cataplexy, and quality of life with oveporexton for patients with narcolepsy.
Researchers assess the differences in out-of-pocket spending on brand name compared with generic medication.
Practical takeaways to improve real‑world clinic outcomes for PAINWeek 2026.
Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
The trial found that up to 25 days of nirmatrelvir-ritonavir did not improve cognitive, autonomic, or exercise-related symptoms compared with placebo.
Advertisement
Advertisement
Trending on Drug Topics
1
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
2
Study Finds No Neurodevelopmental Risk in Prenatal COVID-19, Except Speech
3
Generic Drug Costs Burdening Patients as Much as Brand Name Options
4
Oveporexton Met Primary, Key Secondary End Points in Phase 3 Studies
5